Phase I study of combination recombinant interleukin-2 and interferon gamma in patients with advanced malignancies.

Molecular biotherapy Pub Date : 1990-06-01
E Hu, K Watkins, S Groshen, S C Chen, B Malloy, R Agah, P Nichols, J Parker, A Martin, M G Boosalis
{"title":"Phase I study of combination recombinant interleukin-2 and interferon gamma in patients with advanced malignancies.","authors":"E Hu,&nbsp;K Watkins,&nbsp;S Groshen,&nbsp;S C Chen,&nbsp;B Malloy,&nbsp;R Agah,&nbsp;P Nichols,&nbsp;J Parker,&nbsp;A Martin,&nbsp;M G Boosalis","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>A phase I trial of interleukin-2 and interferon gamma combination treatment in patients with advanced malignancies was performed based on preclinical in vitro and in vivo data which demonstrated synergistic antitumor effect. The toxicities, immune parameters, and tumor responses are described. The clinical and biologic maximal tolerated doses were extrapolated from these data.</p>","PeriodicalId":18809,"journal":{"name":"Molecular biotherapy","volume":"2 2","pages":"96-103"},"PeriodicalIF":0.0000,"publicationDate":"1990-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular biotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

A phase I trial of interleukin-2 and interferon gamma combination treatment in patients with advanced malignancies was performed based on preclinical in vitro and in vivo data which demonstrated synergistic antitumor effect. The toxicities, immune parameters, and tumor responses are described. The clinical and biologic maximal tolerated doses were extrapolated from these data.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
重组白细胞介素-2和γ干扰素联合治疗晚期恶性肿瘤的I期研究。
基于临床前体外和体内数据,进行了白细胞介素-2和干扰素γ联合治疗晚期恶性肿瘤患者的I期试验,显示出协同抗肿瘤作用。描述了毒性、免疫参数和肿瘤反应。临床和生物学上的最大耐受剂量是从这些数据推断出来的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Innovation in science. Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha. The role of cytokines in tumor immunotherapy. Report on the 2nd Frankfurt International Cytokine Symposium 25-27 June 1992, Frankfurter Hof, Frankfurt, Germany. Relation between the biologic activities and chemical structures of synthetic microbial lipopeptide analogs in mice. Antitumor effect of recombinant human tumor necrosis factor-alpha analog combined with desmuramyl dipeptides LK-409 or LK-410 on sarcoma in mice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1